Merck & CIE, et al. v. Watson Laboratories, Inc., C.A. Nos. 13-978 – RGA; Merck & CIE, et al. v. Watson Laboratories, Inc., C.A. No. 13-1272 - RGA, August 31, 2015 ...
WAYNE, N.J. — The Food and Drug Administration has approved a new oral contraceptive developed by Bayer. Safyral is a combination of Yasmin, also developed by Bayer, with 451 mcg levomefolate calcium, ...
Bayer HealthCare announced the approval of Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets), an oral contraceptive that raises folate levels in ...
WAYNE, N.J., Dec. 16, 2010 Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL(TM) (drospirenone 3 mg ...
Bayer HealthCare Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), Safyral (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ ...
Actavis, Inc. recently confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market drospirenone/ethinyl ...
Safyral is engineered to reduce the risks of rare neural tube defects. Combination oral contraceptives reduce the risk of pregnancy primarily by inhibiting ovulation. This product combines ...
Lupin has received final approval for its Tydemy from the United States Food and Drug Administration to market a generic version of Safyral Tablets of Bayer Healthcare Pharmaceuticals Inc.Source : BSE ...
> Celgene's ($CELG) blood cancer drug Revlimid won a new indication for patients with mantle cell lymphoma that have relapsed after other therapies; the new use is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results